No Prescription |
 |
 | ||
|
Carvidon MR Vastarel MR |
|
| ||
No Prescription » Prescription Drugs 3 » Carvidon MR Vastarel MR Trimetazidine is a drug for angina pectoris sometimes referred to by the brand name Vastarel MR.Prophylactic treatment of episodes of angina pectoris ( Chest pain ). Buy Carvidon MR Vastarel MR and other Prescription Drugs 3 products online at Medstore. Buy Online at Medstore - Click Here!
About Carvidon MR Vastarel MR: Product Type: Prescription Drugs 3 Carvidon MR (Vastarel MR Generic Trimetazidine) Carvidon MR (Vastarel MR Generic Trimetazidine) Vastarel MR Generic Trimetazidine 35mg 420(2 x 210) Tablets 210 Tablets Vastarel MR Generic Trimetazidine Carvidon MR
View more Prescription Drugs 3 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
